Biomedical subjects

Peter Bräunig

Publications and source records attributed to Peter Bräunig.

15 recordsLinked to original sources

PubMed2006

A simple fluorescent double staining method for distinguishing neuronal from non-neuronal cells in the insect central nervous system.

Being able to discriminate between neurons and non-neuronal cells such as glia and tracheal cells has been a major problem in insect neuroscience, because glia-specific antisera are available for only a small number of species such as Drosophila melanogaster and Manduca sexta. Especially developmental or comparative studies often require an estimate of neuron numbers. Since neuronal and glial cell bodies are in many cases indiscernible in situ, a method to distinguish neurons from non-neuronal cells that works in any given species is wanting. Another application is cell culturing. Cultured cells usually change their outward shape dramatically after being isolated so that it is frequently impossible to tell neurons and glia apart. Here, we present a simple method that uses a commercially available antiserum directed against horseradish peroxidase, which specifically stains neurons but no other cell type in every insect species investigated. Counterstaining with DAPI, a fluorescent chromophore that binds to double-stranded DNA in the nuclei of all cells, yields the total number of cells in a given sample. Thus, double labeled cells can be identified as neurons, cells that carry only DAPI staining are non-neuronal.

Animals↗

PubMed2006

[Pharmacotherapy of manic-depressive mixed States].

OBJECTIVE: Mixed episodes comprise up to 40 % of acute bipolar admissions. They are difficult-to-treat, complex clinical pictures. This review provides an overview of the available literature on the pharmacotherapy of manic-depressive mixed states and suggests treatment options. METHOD: Literature was identified by searches in Medline, Embase and the Cochrane Controlled Trials Register. Studies were considered relevant if they contained the keywords mixed mania, mixed state (s), mixed episode (s), treatment, therapy, study or trial. RESULTS: Overall, there were very few double-blind, placebo-controlled studies specifically designed to treat manic-depressive mixed states. Rather, patients with mixed states comprised a subgroup of the examined patient cohorts. Nevertheless, the data show that acute mixed states do not respond favourably to lithium. Instead, valproate and olanzapine are drugs of first choice. Carbamazepine may play a role in the prevention of mixed states. Antidepressants should be avoided, because they may worsen intraepisodic mood lability. Lamotrigine may be useful in treating mixed states with predominantly depressive symptoms. CONCLUSIONS: More treatment studies specifically designed to treat the complex clinical picture of mixed states are clearly needed. Current treatment recommendations for clinical practice based on the available literature can only target selected aspects of these episodes.

Anticonvulsants↗

PubMed2006

[Psychotherapy in bipolar disorders -- randomised controlled trials of treatment efficacy].

On the basis of a vulnerability-stress-model psycho-educative, cognitive-behavioural, family-oriented and interpersonal approaches of psychotherapy for bipolar disorders are described. This is followed by a review of randomised controlled trials investigating the treatment efficacy of psychotherapeutic interventions. These studies show positive results particularly for psychoeducation, cognitive-behavioural therapy and family-oriented therapy. Finally, it is discussed in which respects evidence for the successful implementation of psychotherapy is still missing and why it is so important to move towards manualized psychotherapeutic programs.

Bipolar Disorder↗

PubMed2006

[Psychotherapy and psychoeducation for bipolar disorders -- manualized treatment programs].

The article provides an overview of published treatment manuals for psychotherapy in bipolar disorders and discusses content and structure of manualized programs. This is followed by a more detailed description of an elaborated psycho-educative program which have successfully been applied in individual as well as in group settings for the education of inpatients, outpatients and patients' relatives. Future research needs to further evaluate existing programs in terms of treatment efficacy.

Bipolar Disorder↗

PubMed2006

[Self-rating scales for manic episodes].

The article provides an overview of clinical self-rating scales for manic symptoms, aiming to promote its use in clinical practice. Of the four identified scales available in German language, the Manie-Selbstbeurteilungs-Skala MSS by Bräunig et al., which is a translation of the Self-Rating Manic Inventory SRMI by Shugar et al., is the best validated instrument both for diagnostic purposes and for measuring symptom severity during the course of illness. This overview is followed by a brief discussion of newer developments in the bipolar spectrum, temperament and hypomania research. In addition, options of using mania scales for measuring hypomania according to DSM-IV and/or ICD-10 criteria for bipolar disorders are suggested.

Bipolar Disorder↗

PubMed2006

[Quetiapine in the treatment of acute mania].

Quetiapine is an atypical antipsychotic that has shown efficacy in the treatment of positive and negative symptoms in schizophrenia without causing extrapyramidal symptoms (EPS). To date, there are two monotherapy and two combination therapy studies with a double blind, placebo-controlled design on the use of quetiapine in mania. Several open studies and case reports support the results of the controlled trials suggesting that quetiapine is effective in treating the broad spectrum of manic symptoms and is tolerated well.

Acute Disease↗

PubMed2006

[Official guidelines for the treatment of acute mania].

There are several national and international practice guidelines on the treatment of acute mania. Their purpose is to assess the available evidence of efficacy for medication used in the treatment of bipolar mania and to grade it according to the quality of studies available. The World Federation of Societies of Biological Psychiatry (WFSBP) has developed such guidelines in 2003. They categorize the scientific quality of the studies into four levels of evidence (A-D) and provide an algorithm based on the degree of severity of the acute manic episode.

Acute Disease↗

PubMed2006

Common and specific inhibitory motor neurons innervate the intersegmental muscles in the locust thorax.

The inhibitory innervation of the intersegmental (body wall) muscles between the first and the second thoracic segment of the migratory locust, Locusta migratoria, was investigated using neuroanatomical, immunocytochemical and electrophysiological techniques. Three neurons located in the prothoracic ganglion show GABA-like immunoreactivity and project into the intersegmental nerve. Two are common inhibitors. One of those innervates the oblique intersegmental muscle M59 and two dorsal longitudinal muscles (M81 and M82). The second common inhibitor also innervates M59 and the ventral longitudinal muscle M60. The third neuron innervates M60 exclusively and, for that reason, has to be regarded as the first specific inhibitor ever observed in insect neuromuscular assemblies. According to their innervation pattern, we term these neurons CI(59/60), CI(59/81/82), and SI(60). CI(59/81/82) and CI(59/60) appear to be segmentally homologous to CI(a) and CI(b) neurons, respectively, in the other body segments.

Animals↗

PubMed2006

Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes.

OBJECTIVE: Some patients with bipolar disorder experience mood episodes following emotional life events, whereas others do not. There is evidence that orbitofrontal hypoactivity may be related to this, because the orbitofrontal cortex is involved in the regulation of emotional and behavioural responses to external events. The close anatomical and functional connection between the orbitofrontal cortex and olfactory processing suggests that patients with bipolar disorder and heightened emotional reactivity may exhibit altered olfactory function compared with patients with bipolar disorder who do not exhibit this sensitivity. METHODS: In this pilot study, olfactory function was assessed in patients with bipolar disorder and a history of event-triggered episodes (n = 7) and in patients with bipolar disorder without such a history (n = 9) at the Department of Psychiatry and the Taste and Smell Clinic of the University of Dresden, Germany. Each patient's bipolar disorder was in remission at study entry, and they were on monotherapy with mood stabilizers. Assessment included olfactory event-related potentials (ERP) and psychophysical tests for odour threshold, odour identification and olfactory quality discrimination. RESULTS: Odour thresholds were lower in patients with bipolar disorder and event-triggered episodes compared with the other patient group. In addition, patients with event-triggered episodes exhibited shorter N1 peak latencies of the olfactory ERP. CONCLUSIONS: Our findings indicate disinhibition of orbitofrontal areas involved in the processing of emotional events in a subset of patients with bipolar illness.

Adult↗

PubMed2005

[Catatonia].

Catatonia is a neuropsychiatric syndrome characterized by mental, motor and behavioral symptoms. It occurs in up to 18 % of acute admissions and is most frequently associated with affective and psychotic disorders. It is also seen in dissociative disorders, pervasive developmental disorders, mental retardation and organic psychiatric disorders. Catatonic syndromes are impressive states that can be reliably and validly diagnosed both clinically and with psychometric measurements and they can be treated effectively. Despite this, they are often not recognized in clinical practice, are not part of the therapeutic strategy and thus remain untreated. The following article is intended to give a review of the most pertinent questions related to the diagnosis and treatment of catatonia in order to improve clinicians' ability to recognize and treat catatonic symptoms and syndromes adequately.

Benzodiazepines↗

PubMed2005

Pharmacotherapy of bipolar mixed states.

OBJECTIVE: Mixed episodes comprise up to 40% of acute bipolar admissions. They are difficult-to-treat, complex clinical pictures. This review provides an overview of the available literature on the pharmacotherapy of manic-depressive mixed states and suggests treatment options. METHOD: Literature was identified by searches in Medline, Embase and the Cochrane Controlled Trials Register. Studies were considered relevant if they contained the keywords mixed mania, mixed state(s), mixed episode(s), treatment, therapy, study or trial. RESULTS: Overall, there were very few double-blind, placebo-controlled studies specifically designed to treat manic-depressive mixed states. Rather, patients with mixed states comprised a sub-group of the examined patient cohorts. Nevertheless, the data show that acute mixed states do not respond favourably to lithium. Instead, valproate and olanzapine are drugs of first choice. Carbamazepine may play a role in the prevention of mixed states. Antidepressants should be avoided, because they may worsen intraepisodic mood lability. Lamotrigine may be useful in treating mixed states with predominantly depressive symptoms. CONCLUSIONS: More treatment studies specifically designed to treat the complex clinical picture of mixed states are clearly needed. Current treatment recommendations for clinical practice based on the available literature can only target select aspects of these episodes.

Anticonvulsants↗

PubMed2004

Projection patterns of posterior dorsal unpaired median neurons of the locust subesophageal ganglion.

Six neurons in a group of dorsal unpaired median (DUM) neurons with cell bodies in the posterior part-maxillary and labial neuromeres-of the subesophageal ganglion of locusts have two axons each that descend into both the left and the right halves of the ganglia of the ventral nerve cord. None of the neurons has peripheral axons, so they are interneurons. Electrophysiology shows that the axons of at least four neurons project to the terminal abdominal ganglion to which they conduct spikes at a velocity of 0.5-0.6 m. second(-1). In the somata, the spikes have a smaller amplitude and briefer duration at half height than the spikes of thoracic, efferent DUM neurons. Each neuron has bilaterally symmetrical branches within the subesophageal ganglion and in the thoracic ganglia. On the basis of the specific patterns of branches, and the neuropiles, tracts, and commissures in which they occur, three types of neurons (DUM SD 1-3) can be recognized. DUM SD 1 and 3 project to ventral regions of neuropile in the thoracic ganglia in which the efferent DUM neurons of these ganglia have no branches. DUM SD 2 projects to dorsal neuropiles. The projection patterns of these putatively octopaminergic neurons suggest that they could be the source of the octopaminergic modulation of networks underlying sensory processing and motor pattern generation within these ganglia. Within this group of posterior DUM neurons, two additional cells were stained that have axons ascending to the brain.

Animals↗

PubMed2003

Relevance of the catatonic syndrome to the mixed manic episode.

BACKGROUND: Catatonic symptoms have been associated with mixed mania in the older psychiatric literature, however, to date no systematic studies have been performed to assess their frequency in these patients. METHOD: Ninety-nine patients with bipolar disorder manic or mixed episode were assessed for the presence of catatonia. RESULTS: Thirty-nine patients fulfilled criteria for mixed mania of whom 24 were catatonic. Among the patients with pure mania, only three were catatonic. Eighteen catatonic patients with mixed mania required admission to the acute care unit (ACU). LIMITATIONS: Our findings only apply to severely ill patients with mixed mania who require ACU admission. Nevertheless, it is important to know, that the likelihood of overlooking catatonia in less severely ill patients with mixed mania is low and that it does not need to be routinely assessed on a general ward. CONCLUSIONS: Catatonia is frequent in mania and linked to the mixed episode. Catatonia in mixed mania is likely to be found among the severely ill group of patients with mixed mania, who require emergency treatment.

Adult↗

PubMed2003

Levetiracetam in the treatment of rapid cycling bipolar disorder.

Levetiracetam (LEV) is a novel anticonvulsant that is currently investigated in bipolar disorder. It may be useful in the treatment of refractory and complicated cases, in which conventional mood stabilizers are not effective. We report two cases of rapid cycling bipolar disorder in which the add-on of LEV to a conventional treatment regimen improved symptoms of depression, as well as those of mania/mixed mania, and disrupted the severe rapid cycling pattern.

Antidepressive Agents↗

PubMedDate not supplied

Factor analysis of the catatonia rating scale and catatonic symptom distribution across four diagnostic groups.

Catatonia is a frequent psychomotor syndrome, which has received increasing recognition over the last decade. The assessment of the catatonic syndrome requires systematic rating scales that cover the complex spectrum of catatonic motor signs and behaviors. The Catatonia Rating Scale (CRS) is such an instrument, which has been validated and which has undergone extensive reliability testing. In the present study, to further validate the CRS, the items composing this scale were submitted to principal components factor extraction followed by a varimax rotation. An analysis of variance (ANOVA) was performed to assess group differences on the extracted factors in patients with schizophrenia, pure mania, mixed mania, and major depression (N=165). Four factors were extracted, which accounted for 71.5% of the variance. The factors corresponded to the clinical syndromes of (1) catatonic excitement, (2) abnormal involuntary movements/mannerisms, (3) disturbance of volition/catalepsy, and (4) catatonic inhibition. The ANOVA revealed that each of the groups showed a distinctive catatonic symptom pattern and that the overlap between diagnostic groups was minimal. We conclude that this four-factor symptom structure of catatonia challenges the current conceptualization, which proposes only two symptom subtypes.

Analysis of Variance↗